CoChat

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

Open access

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20112738

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. RAG2−/−x γc−/− mice are more susceptible to MCA-induced sarcomas than syngeneic RAG2−/− and WT mice. The indicated dose of MCA was injected into the subcutaneous space of mice, and sarcoma formation was monitored over time. All cohorts consisted of 20 mice. Tumor-positive mice were defined as those that harbored a progressively growing mass ≥25 mm2. Similar results were found in a repeat experiment that included the 5 and 25 µg doses.
Figure 1. RAG2−/−x γc−/− mice are more susceptible to MCA-induced sarcomas than syngeneic RAG2−/− and WT mice. The indicated dose of MCA was injected into the subcutaneous space of mice, and sarcoma formation was monitored over time. All cohorts consisted of 20 mice. Tumor-positive mice were defined as those that harbored a progressively growing mass ≥25 mm2. Similar results were found in a repeat experiment that included the 5 and 25 µg doses.CC BY-NC-SA · PubMed Central
Figure 2. Generation of MCA sarcoma cell lines of varying immunogenicities to study cancer immunoediting by innate and adaptive immunity. (A) The carcinogen MCA is administered to syngeneic mice with three levels of immune function. (n ≥ 20 mice for each cohort). (B) The immunogenicity of the MCA sarcomas is postulated to be heterogeneous. (C) MCA sarcoma cell lines are generated from each tumor mass and transplanted into syngeneic WT mice (n > 5 for each cell line) to assess growth. (D) Shown is the % growth of each cell line after transplant into WT mice. Cell lines that grow in <51% of the mice are termed regressors. Cell lines that grow in >50% of mice are termed progressors. (E) For each genotype, the percentage of tumor cell lines that displayed a regressor growth pattern is plotted. The “percent regressor tumors” is postulated to be inversely correlated with the quantity of immune pressure that is occurring during tumor formation in each mouse genotype.
Figure 2. Generation of MCA sarcoma cell lines of varying immunogenicities to study cancer immunoediting by innate and adaptive immunity. (A) The carcinogen MCA is administered to syngeneic mice with three levels of immune function. (n ≥ 20 mice for each cohort). (B) The immunogenicity of the MCA sarcomas is postulated to be heterogeneous. (C) MCA sarcoma cell lines are generated from each tumor mass and transplanted into syngeneic WT mice (n > 5 for each cell line) to assess growth. (D) Shown is the % growth of each cell line after transplant into WT mice. Cell lines that grow in <51% of the mice are termed regressors. Cell lines that grow in >50% of mice are termed progressors. (E) For each genotype, the percentage of tumor cell lines that displayed a regressor growth pattern is plotted. The “percent regressor tumors” is postulated to be inversely correlated with the quantity of immune pressure that is occurring during tumor formation in each mouse genotype.CC BY-NC-SA · PubMed Central
Figure 3. A majority of MCA-induced sarcoma cell lines derived from RAG2−/−x γc−/− mice cannot form tumors when transplanted into syngeneic WT mice. MCA-induced sarcoma cell lines were derived from tumors generated in syngeneic C57BL/6-strain WT, RAG2−/−, and RAG2−/−x γc−/− mice. These cell lines were transplanted into syngeneic RAG2−/− (n ≥ 2 for each cell line) or WT (n ≥ 5 for each cell line) hosts, and tumor growth was measured over time. (A) The mean growth for each cell line is shown (open symbols = regressor cell lines; closed symbols = progressor cell lines). (B) The percentage of WT mice that developed tumors is shown for group of cell lines. Tumor-free mice were defined as having a nonenlarging mass <9 mm in average diameter. The number of cell lines and mice are indicated in the figure.
Figure 3. A majority of MCA-induced sarcoma cell lines derived from RAG2−/−x γc−/− mice cannot form tumors when transplanted into syngeneic WT mice. MCA-induced sarcoma cell lines were derived from tumors generated in syngeneic C57BL/6-strain WT, RAG2−/−, and RAG2−/−x γc−/− mice. These cell lines were transplanted into syngeneic RAG2−/− (n ≥ 2 for each cell line) or WT (n ≥ 5 for each cell line) hosts, and tumor growth was measured over time. (A) The mean growth for each cell line is shown (open symbols = regressor cell lines; closed symbols = progressor cell lines). (B) The percentage of WT mice that developed tumors is shown for group of cell lines. Tumor-free mice were defined as having a nonenlarging mass <9 mm in average diameter. The number of cell lines and mice are indicated in the figure.CC BY-NC-SA · PubMed Central
Figure 4. The frequency of regressor cell lines is greater from tumors generated in RAG2−/−x γc−/− mice compared with WT and other immune deficient mice. A summary of two MCA-induction experiments performed in this manuscript is plotted in the context of previous MCA-induction experiments. Previously published experiments are included for comparison purposes and are from previous studies (Shankaran et al., 2001; Dunn et al., 2005; Koebel et al., 2007). Absolute numbers of regressors/total number of cell lines tested is shown next to the bar for each experiment.
Figure 4. The frequency of regressor cell lines is greater from tumors generated in RAG2−/−x γc−/− mice compared with WT and other immune deficient mice. A summary of two MCA-induction experiments performed in this manuscript is plotted in the context of previous MCA-induction experiments. Previously published experiments are included for comparison purposes and are from previous studies (Shankaran et al., 2001; Dunn et al., 2005; Koebel et al., 2007). Absolute numbers of regressors/total number of cell lines tested is shown next to the bar for each experiment.CC BY-NC-SA · PubMed Central
Figure 5. RAG2−/−x γc−/− regressors are edited when transplanted into RAG2−/− mice, but are not specifically recognized by NK cells. Two independent MCA-induced sarcoma cell lines generated from RAG2−/−x γc−/− mice were transplanted into syngeneic RAG2−/−x γc−/− or RAG2−/− mice, and tumor masses were harvested at day 25 and converted into “passaged” daughter cell lines, which were transplanted into syngeneic WT mice (number of cell lines and mice are shown in the figure), and (A) the percentage of WT mice that remained tumor-free is shown for each group of cell lines. Tumor-free mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. (B) MCA sarcoma cell lines were cultured with IL-2–activated NK cells in a 5-h chromium release cytotoxicity assay and specific lysis normalized to YAC-1–specific lysis is plotted for each cell line based on immune background and phenotype. (C) Regressor and progressor cell lines were transplanted into RAG-deficient mice and analyzed for infiltrating NK cells by FACS.
Figure 5. RAG2−/−x γc−/− regressors are edited when transplanted into RAG2−/− mice, but are not specifically recognized by NK cells. Two independent MCA-induced sarcoma cell lines generated from RAG2−/−x γc−/− mice were transplanted into syngeneic RAG2−/−x γc−/− or RAG2−/− mice, and tumor masses were harvested at day 25 and converted into “passaged” daughter cell lines, which were transplanted into syngeneic WT mice (number of cell lines and mice are shown in the figure), and (A) the percentage of WT mice that remained tumor-free is shown for each group of cell lines. Tumor-free mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. (B) MCA sarcoma cell lines were cultured with IL-2–activated NK cells in a 5-h chromium release cytotoxicity assay and specific lysis normalized to YAC-1–specific lysis is plotted for each cell line based on immune background and phenotype. (C) Regressor and progressor cell lines were transplanted into RAG-deficient mice and analyzed for infiltrating NK cells by FACS.CC BY-NC-SA · PubMed Central
Figure 6. MHC class II+ macrophages preferentially infiltrate unedited regressors. (A) Representative images of tumor sections from RAG2−/− or RAG2−/−x γc−/− hosts stained for MHC class II. (B) Quantification of MHC class II+ events and CD68+ events in tumor sections is shown. (C–E) Regressor and progressor cell lines were transplanted into RAG2−/− mice and analyzed for activated MHC class II+ macrophages. (C) Representative FACS plots of three regressor and three progressor tumors are shown. Cells were gated on a CD45+PI− population. (D) Percentages of activated monocyte-lineage (F4/80+) cell populations are shown for regressor and progressor tumor masses. Each symbol represents a different tumor cell line transplanted into 1–3 RAG2−/− mice. (E) Frozen tumor sections of progressor and regressor tumor masses growing in RAG2−/− mice were stained for MHC class II. Nuclei were counterstained with hematoxylin. Bar, 100 μm. **, P < 0.01. Error bars are represented by ± SEM. IHC results were reproduced at least once.
Figure 6. MHC class II+ macrophages preferentially infiltrate unedited regressors. (A) Representative images of tumor sections from RAG2−/− or RAG2−/−x γc−/− hosts stained for MHC class II. (B) Quantification of MHC class II+ events and CD68+ events in tumor sections is shown. (C–E) Regressor and progressor cell lines were transplanted into RAG2−/− mice and analyzed for activated MHC class II+ macrophages. (C) Representative FACS plots of three regressor and three progressor tumors are shown. Cells were gated on a CD45+PI− population. (D) Percentages of activated monocyte-lineage (F4/80+) cell populations are shown for regressor and progressor tumor masses. Each symbol represents a different tumor cell line transplanted into 1–3 RAG2−/− mice. (E) Frozen tumor sections of progressor and regressor tumor masses growing in RAG2−/− mice were stained for MHC class II. Nuclei were counterstained with hematoxylin. Bar, 100 μm. **, P < 0.01. Error bars are represented by ± SEM. IHC results were reproduced at least once.CC BY-NC-SA · PubMed Central
Figure 7. NK cells and IFN-γ are necessary for innate editing of a regressor tumor and M1 macrophage accumulation. Regressor cell line 2 was transplanted into RAG2−/− mice treated with anti-NK1.1, IFN-γ–blocking antibody, or control antibody, after which tumor growth was measured and passaged cell lines were generated. (A and B) The passaged cell lines were then transplanted into syngeneic WT hosts (number of cell lines and mice are indicated) and tumor-free survival was measured. Tumor-free mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. Tumor sections from RAG2−/− hosts were stained for MHC class II (C) and quantitated (D). *, P < 0.05. Error bars are represented by ± SEM. Results were reproduced at least once.
Figure 7. NK cells and IFN-γ are necessary for innate editing of a regressor tumor and M1 macrophage accumulation. Regressor cell line 2 was transplanted into RAG2−/− mice treated with anti-NK1.1, IFN-γ–blocking antibody, or control antibody, after which tumor growth was measured and passaged cell lines were generated. (A and B) The passaged cell lines were then transplanted into syngeneic WT hosts (number of cell lines and mice are indicated) and tumor-free survival was measured. Tumor-free mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. Tumor sections from RAG2−/− hosts were stained for MHC class II (C) and quantitated (D). *, P < 0.05. Error bars are represented by ± SEM. Results were reproduced at least once.CC BY-NC-SA · PubMed Central
Figure 8. NK cells and IFN-γ are required to polarize TAMs toward an M1-type phenotype. Regressor cell line 2 was transplanted into syngeneic RAG2−/− mice (injected with isotype control, anti-NK1.1, or anti–IFN-γ monoclonal antibodies) or RAG2−/−x γc−/− mice. Tumor masses were harvested 15 d after transplantation, disaggregated into single-cell suspensions, and analyzed by IHC (A) or FACS (B) to measure the percentage of M1 and M2 macrophages as defined by MHC class II and CD206 expression of CD68+ events (for IHC) or MHC class II and Ly6C expression of CD11b+ populations (for FACS), respectively. (C and D) An example of the flow cytometry gating to quantitate M1 and M2 macrophages. M1 macrophages are 7AAD−, CD45+, Ly 6Clo, MHC class IIhi, F4/80+, CD206lo cells. M2 macrophages are 7AAD−, CD45+, Ly6Clo, MHC classIIlo, F4/80+, CD206hi cells. (E) Cultured supernatant from single-cell suspensions were assessed for production of the indicated cytokines after 24 h of culture. (F) TAMs were sorted from harvested tumors at day 15, and genes associated with classically activated M1 type genes, such as iNOS and TNF, or alternatively activated M2 type genes, such as Arginase, eCAD, and Gas3, were measured by quantitative PCR. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars are represented by ± SEM. Each symbol represents a different mouse. Results were reproduced at least once.
Figure 8. NK cells and IFN-γ are required to polarize TAMs toward an M1-type phenotype. Regressor cell line 2 was transplanted into syngeneic RAG2−/− mice (injected with isotype control, anti-NK1.1, or anti–IFN-γ monoclonal antibodies) or RAG2−/−x γc−/− mice. Tumor masses were harvested 15 d after transplantation, disaggregated into single-cell suspensions, and analyzed by IHC (A) or FACS (B) to measure the percentage of M1 and M2 macrophages as defined by MHC class II and CD206 expression of CD68+ events (for IHC) or MHC class II and Ly6C expression of CD11b+ populations (for FACS), respectively. (C and D) An example of the flow cytometry gating to quantitate M1 and M2 macrophages. M1 macrophages are 7AAD−, CD45+, Ly 6Clo, MHC class IIhi, F4/80+, CD206lo cells. M2 macrophages are 7AAD−, CD45+, Ly6Clo, MHC classIIlo, F4/80+, CD206hi cells. (E) Cultured supernatant from single-cell suspensions were assessed for production of the indicated cytokines after 24 h of culture. (F) TAMs were sorted from harvested tumors at day 15, and genes associated with classically activated M1 type genes, such as iNOS and TNF, or alternatively activated M2 type genes, such as Arginase, eCAD, and Gas3, were measured by quantitative PCR. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars are represented by ± SEM. Each symbol represents a different mouse. Results were reproduced at least once.CC BY-NC-SA · PubMed Central
Figure 9. In vivo administration of CD40 agonist in RAG2−/−x γc−/− mice induces effective immunoediting and intratumoral M1 macrophages. Regressor cell line 2 was transplanted into RAG2−/−x γc−/− mice receiving a single dose of either control rat IgG or anti-CD40 agonistic monoclonal antibodies on day 5. Tumor growth was measured over time. (A) Tumor masses were converted into passaged daughter cell lines which were transplanted into syngeneic WT mice and assessed for tumor formation (number of cell lines and mice are indicated in the figure). Tumor-free mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. (B) At day 15 after transplantation, tumor masses were disaggregated into single-cell suspensions, and the percentage of M1 (top) and M2 (bottom) macrophages of CD11b+ events for each condition were quantified. *, P < 0.05; ***, P < 0.001. Error bars are represented by ± SEM. Each symbol represents a different mouse. Results were reproduced at least once.
Figure 9. In vivo administration of CD40 agonist in RAG2−/−x γc−/− mice induces effective immunoediting and intratumoral M1 macrophages. Regressor cell line 2 was transplanted into RAG2−/−x γc−/− mice receiving a single dose of either control rat IgG or anti-CD40 agonistic monoclonal antibodies on day 5. Tumor growth was measured over time. (A) Tumor masses were converted into passaged daughter cell lines which were transplanted into syngeneic WT mice and assessed for tumor formation (number of cell lines and mice are indicated in the figure). Tumor-free mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. (B) At day 15 after transplantation, tumor masses were disaggregated into single-cell suspensions, and the percentage of M1 (top) and M2 (bottom) macrophages of CD11b+ events for each condition were quantified. *, P < 0.05; ***, P < 0.001. Error bars are represented by ± SEM. Each symbol represents a different mouse. Results were reproduced at least once.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 348

Metadata

Authors
O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
Affiliations
  • University of California San Diego (US)
  • Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
  • University of Brescia (IT)
  • Washington University in St. Louis (US)
  • Center for Immunology, Department of Pathology and Immunology 3 and 4
  • The University of Melbourne (AU)
Corresponding author
Bui, Jack D.
Venue
Journal of Experimental Medicine
Published
2012-08-27
Volume
209
Issue
10
Pages
1869-1882
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2144577255
Cited by
348
References
58
Citations by year
2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
FWCI
11.05
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
Funders
  • Cancer Research Institute
  • Concern Foundation
  • Hartwell Foundation (CA157885)
  • Ludwig Institute for Cancer Research
  • Cancer Research Coordinating Committee
  • National Institutes of Health (CA157885)
  • Medical Research Council
  • National Health and Medical Research Council
  • National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
  • National Center for Research Resources (C06RR012466)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
MeSH terms
Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.